November 1, 2026

The Journey of Eliza O’Neill and Her Fight Against Sanfilippo Syndrome

In 2015, Glenn, Beckham, Cara, and Eliza O’Neill smiled for a family photo. Eliza had Sanfilippo syndrome, a rare inherited disease. Her mother, Cara O’Neill, worked as a pediatrician in Columbia, S.C.

Eliza loved accessories, often wearing hats or scarfs. Early signs of concern appeared when Eliza was 3. She lagged in reaching developmental milestones and was diagnosed with a pragmatic speech delay. Despite knowing many words, she struggled to use them in social settings.

In 2013, a colleague of Cara’s suggested testing Eliza for metabolic disorders. The test confirmed Sanfilippo syndrome. This disease leaves children with a faulty gene that prevents breaking down heparin sulfate, leading to severe health issues. Children with Sanfilippo lose the ability to speak and walk, have seizures, and often don’t live past their teens. The O’Neills started the Cure Sanfilippo Foundation to raise awareness and funds.

Glenn O’Neill took time to process the diagnosis. Realizing the rapid progression of the disease, Glenn and Cara decided to act quickly.

Researching a Treatment

At Nationwide Children’s Hospital in Columbus, Ohio, researcher Haiyan Fu had explored gene therapy for Sanfilippo syndrome since the late 1990s. Her approach used a modified virus to deliver a functioning gene to patients’ cells.

“If we treat early, it could be potentially a cure,” Fu noted.

Financial constraints in 2009 almost halted her research, but families impacted by Sanfilippo provided funding through foundations like Ben’s Dream. These efforts helped move the research toward human trials.

Raising the Money

The O’Neills needed funds for a clinical trial, which was expensive. Glenn had the idea of creating a viral video. Filmmaker Benjamin Von Wong helped them produce the Saving Eliza video in 2014. The video raised over $2 million, breaking GoFundMe records at that time.

This funding enabled the first human trial in May 2016. The positive results attracted biotech industry interest. In 2022, Ultragenyx acquired the therapy rights and pursued FDA approval. The FDA approved the gene therapy, named Fayuvi, in September.

Fayuvi benefits younger patients more significantly because they have less brain degeneration. It’s priced at nearly $4 million, but Ultragenyx is committed to ensuring all patients can access treatment.

“There should be no logistical barriers to treatment,” said Emil Kakkis, CEO of Ultragenyx.

Despite the positive outcome, Fu and families shared mixed emotions, reflecting on the lengthy process and the children lost along the way.

Eliza’s Progress

Eliza, now almost 17, was the first to receive the therapy in 2016. Though she lost her speech before treatment, she uses picture cards and devices to communicate. She attends school and enjoys activities like swimming.

“I just feel proud of my girl,” Glenn O’Neill expressed. “It’s been tough for her, but she’s very lucky.”

TAGS: